The Role of Biomarkers in the Diagnosis and Management of Pneumonia

Sarah Sungurlu, Robert A. Balk

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Biomarkers are used in the diagnosis, severity determination, and prognosis for patients with community-acquired pneumonia (CAP). Selected biomarkers may indicate a bacterial infection and need for antibiotic therapy (C-reactive protein, procalcitonin, soluble triggering receptor expressed on myeloid cells). Biomarkers can differentiate CAP patients who require hospital admission and severe CAP requiring intensive care unit admission. Biomarker-guided antibiotic therapy may limit antibiotic exposure without compromising outcome and thus improve antibiotic stewardship. The authors discuss the role of biomarkers in diagnosing, determining severity, defining the prognosis, and limiting antibiotic exposure in CAP and ventilator-associated pneumonia patients.

Original languageEnglish (US)
Pages (from-to)691-701
Number of pages11
JournalClinics in Chest Medicine
Issue number4
StatePublished - Dec 2018
Externally publishedYes


  • Biomarkers
  • Pneumonia diagnosis
  • Procalcitonin
  • Prognosis
  • Scoring systems

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'The Role of Biomarkers in the Diagnosis and Management of Pneumonia'. Together they form a unique fingerprint.

Cite this